Login to Your Account

Menopause Spray Brings 3Q Profit

Vivus Starts Phase III Effort With Obesity Combo Qnexa

By Randall Osborne

Monday, November 12, 2007
Riding on third-quarter profits that surprised some analysts thanks to the sale of its spray drug for menopause symptoms earlier this year, Vivus Inc. began the first of two pivotal Phase III trials with Qnexa, the combination phentermine/topiramate drug dosed once daily for obesity. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription